Rituximab Matches Standard Therapy in Early MS: Key Results from the OVERLORD-MS Trial
A landmark study published in the New England Journal of Medicine provides strong evidence that a lower-cost treatment option for multiple sclerosis (MS) may perform as well as one of the current standards of care.
By: Nele Vanbilsen
Published:
The OVERLORD-MS trial, conducted across Norway and Sweden, compared two B-cell depleting therapies, rituximab and ocrelizumab, in patients with newly diagnosed relapsing MS. Over 30 months of follow-up, the study delivers important insights with both clinical and global health implications.
Key findings
The trial showed that:
- Rituximab was as effective as ocrelizumab in controlling disease activity over 30 months
- Safety profiles were comparable between the two treatments
- Findings support the use of early, high-efficacy B-cell depletion in newly diagnosed MS
These results suggest that effective disease control in early MS may not necessarily depend on higher-cost therapies, potentially reshaping how treatment strategies are considered in different healthcare settings.
Part of the EBV-MS research initiative
Importantly, the OVERLORD-MS trial is embedded within the EU-funded EBV-MS project, which investigates the role of Epstein–Barr virus (EBV) in the development and progression of multiple sclerosis.
Because both rituximab and ocrelizumab target B cells, the main reservoir for latent EBV infection, the study also provides valuable biological material. These samples are now being used to explore how B-cell depletion influences EBV-related immune mechanisms in MS, helping to bridge clinical outcomes with disease biology.
Why this matters
Beyond its clinical findings, the study has broader implications:
- It supports the possibility of more affordable high-efficacy MS treatment options
- It may help improve global access to effective therapies, particularly in settings where cost is a major barrier
- It strengthens the evidence base for early intervention with high-efficacy treatment strategies
Publicly funded, independently driven research
The OVERLORD-MS trial was coordinated by Neuro-SysMed (external link)and supported through Norway’s national clinical trials program KLINBEFORSK (external link). It stands as an example of how publicly funded academic research can generate high-quality evidence with direct relevance for patient care and healthcare policy.
Looking ahead
As MS research continues to evolve, studies like OVERLORD-MS highlight an important shift: advancing not only more effective therapies, but also more accessible ones. At the same time, its integration within the EBV-MS initiative underscores the growing focus on understanding the viral and immunological drivers of the disease.
Together, these findings represent a meaningful step toward more equitable and biologically informed MS care.